bpc-157 human clinical trials safety 2025 for athletes and injury treatment: Science, safety, and legal concerns ๐๐ปโโ๏ธ Is the lack of
Description
Al Aisari F, Al-Hashmi H, Mula-Abed WA
Given its regenerative properties and favorable safety profile, AOD9604 holds promise as a novel therapeutic agent for OA, especially when used in conjunction with established treatments like HA [1]
Skipping doses, altering times, or only dosing a few times per week can reduce results
For example, metformin can increase the risk of B12 deficiency, while blood thinners or some antibiotics may require special consideration
If you do not see improvement after a few months, consult your healthcare provider
The research base is limited, and the FDA does not approve BPC-157 for human use
